TOPICORT LP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPICORT LP (TOPICORT LP).
Topicort LP (desoximetasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to intracellular glucocorticoid receptors, leading to modulation of gene expression that suppresses inflammatory mediators such as prostaglandins, leukotrienes, and cytokines.
| Metabolism | Topical corticosteroids are metabolized primarily in the skin and then systemically via hepatic pathways, including glucuronidation and sulfation, with subsequent renal excretion. |
| Excretion | Primarily renal (urinary excretion of metabolites and unchanged drug). Biliary/fecal elimination is minimal, accounting for <5% of the dose. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours after topical application. This short half-life reflects rapid systemic clearance and minimal accumulation with once-daily dosing. |
| Protein binding | Approximately 90% bound primarily to albumin and corticosteroid-binding globulin (transcortin). |
| Volume of Distribution | Volume of distribution is not well-defined for topical corticosteroids; systemic absorption is minimal, and Vd is not typically reported. After systemic absorption, corticosteroids distribute widely; for betamethasone dipropionate, the apparent Vd is approximately 1-2 L/kg. |
| Bioavailability | Topical application: Systemic bioavailability is <5% under normal conditions (intact skin). Bioavailability increases with occlusive dressings, inflamed skin, or use on large surface areas. No oral or parenteral bioavailability data are clinically relevant for this topical product. |
| Onset of Action | Topical application: Onset of clinical effect (e.g., reduction of inflammation and pruritus) is typically within 1-2 weeks of twice-daily application. For occlusion therapy, onset may be faster (3-7 days). |
| Duration of Action | Topical application: Duration of clinical effect after a single application is approximately 12-24 hours, supporting once- or twice-daily dosing. Prolonged use may lead to tachyphylaxis. |
Apply a thin film to the affected skin areas twice daily. Route: topical. Frequency: twice daily.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Use lowest effective dose for shortest duration; apply sparingly to limited areas. Not recommended for children under 2 years due to increased systemic absorption. |
| Geriatric use | Use with caution; apply sparingly to limited areas due to thinner skin and increased potential for systemic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOPICORT LP (TOPICORT LP).
| Breastfeeding | It is unknown if desoximetasone is excreted in human milk. Topical application to the breast should be avoided before nursing. M/P ratio not available. Use caution and apply to smallest area for shortest time. |
| Teratogenic Risk | Topical corticosteroids, including TOPICORT LP (desoximetasone), are generally considered low risk for teratogenicity when used sparingly on small areas. However, first trimester use is associated with a small increased risk of orofacial clefts (odds ratio ~1.3). Second and third trimester use may cause fetal growth restriction and adrenal suppression if large amounts are used systemically. Use lowest potency for shortest duration. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to desoximetasone or any component of the formulation.","Untreated bacterial, fungal, or viral infections at the application site."]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency after withdrawal.","Use in children may increase susceptibility to systemic toxicity due to higher skin surface-to-body mass ratio.","Avoid prolonged use on face, intertriginous areas, or under occlusive dressings.","Local adverse reactions include atrophy, striae, telangiectasias, and allergic contact dermatitis."] |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth via ultrasound if prolonged use over large body surface area. Assess maternal adrenal function (ACTH stimulation test) if high-potency or extensive use. Observe neonate for signs of adrenal suppression if maternal use near term or in high doses. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available. |